BioWorld

Category Archives: Stem cell

He Said What?!?! Best Biotech Quotes of 2011

December 29, 2011 – 3:26 pm

As BioWorld Insight readers know, our “Word on the Street” column provides a sample of the most entertaining and thought-provoking quotes our staff stumbles upon each week. Some are gathered during interviews, some gleaned from analyst reports, and some overheard…

Share
By Trista Morrison | Also posted in Accelerated approval, Antibody, Big pharma, Biologic, Biosimilar, Biotech conferences, Biotechnology, BLA, Cancer, Cardiovascular, Clinic, Clinical Trial, Collaboration, Complete Response Letter, Deals, Drug Approval, European Medicines Agency, FDA, Financing, Gene Therapy, Genomics, Healthcare reform, immunotherapy, IND, Investigational New Drug Application, IPO, NDA, New Drug Application, Orphan disease, Patents, PDUFA, Personalized medicine, Pharmaceutical, Phase I, Phase II, Phase III, Pipeline, Preclinical, Rare disease, Reimbursement, RNAi, siRNA, Supplemental new drug application, Uncategorized, venture captial | Tagged , , , | Comments (2)

Can Other Cell Therapy Firms Avoid Dendreon’s Fate?

December 7, 2011 – 5:43 pm

Stem cell therapies may be relatively early stage, but that hasn’t stopped their developers from giving some serious thought to late stage issues like reimbursement and health economics.

Share
By Trista Morrison | Also posted in Reimbursement | Tagged , , , | Comments (0)